MAPT and Mental deterioration: In addition to the anti‐Aβ therapies, anti‐tau therapies using anti‐tau antibodies18 or intrathecal administration of antisense oligonucleotides targeting tau19 should address the tau‐mediated neurodegeneration that occurs downstream of Aβ and is responsible for cognitive decline.